Compare SLDB & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDB | IGD |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.0M | 507.9M |
| IPO Year | 2017 | N/A |
| Metric | SLDB | IGD |
|---|---|---|
| Price | $6.43 | $6.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $18.71 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 196.3K |
| Earning Date | 11-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.15% |
| EPS Growth | ★ 34.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,094,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.65 | $5.58 |
| 52 Week High | $11.45 | $6.74 |
| Indicator | SLDB | IGD |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 38.23 |
| Support Level | $6.25 | $6.01 |
| Resistance Level | $6.58 | $6.39 |
| Average True Range (ATR) | 0.50 | 0.12 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 30.12 | 9.52 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.